Fig. 4

The mutational processes are associated with the somatic status and the genetic burden of ZNF750. The activity of the “NpCpG” (a) and “AID/APOBEC-2” signature (b) is associated with the somatic ZNF750 statuses. The FDR is based on the adjusted Wilcoxon rank-sum test P values. The activity of the “NpCpG” (c) and “AID/APOBEC-2” signature (d) is associated with the genetic burden of ZNF750. The FDR is based on the adjusted SKAT P values, with the effects of the age, the clinical stage and ancestry being corrected. The effects of the somatic status and the genetic burden of ZNF750 on the activity of the “NpCpG” signature (e) and the “AID/APOBEC-2” signature (f) are shown with other clinical features. The P values are based on multivariate linear regression analysis: *P < 0.05, **P < 0.01, ***P < 0.001